LCS
ALLO icon

Levin Capital Strategies’s Allogene Therapeutics ALLO Stock Holding History

Levin Capital Strategies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Hold
13,125
– – ﹤0.01% 231
2025
Q4 		$18K Sell
13,125
-39,375
-75% -$51.9K ﹤0.01% 215
2025
Q3 		$65.1K Buy
+52,500
New +$62.6K 0.01% 215

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Levin Capital Strategies's ALLO Position: Q1 2026 in Review

Levin Capital Strategies held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 13,125 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #231.

Levin Capital Strategies first reported a position in ALLO in Q3 2025 and has held it in 3 quarters since. The position peaked at $65.1K in Q3 2025. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Levin Capital Strategies held 13,125 shares of Allogene Therapeutics worth $32K as of Q1 2026.
  • Levin Capital Strategies left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Levin Capital Strategies's portfolio in Q1 2026, its #231 holding.
  • Levin Capital Strategies first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Levin Capital Strategies's Allogene Therapeutics position peaked at $65.1K in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Levin Capital Strategies's 13F filing for Q1 2026, filed 13 May 2026.